CBTi followed by CPT

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria

There was little evidence of symptom deterioration at 20 weeks and no differences between conditions. No participants met PTSD or depression deterioration criteria. One participant in each condition m

Effect: null; 1 participant per condition met insomnia deterioration criteria; 0 met PTSD or depression deterioration criteria